FEED · ENvue Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“we do not have sufficient resources to fund our operations for the next twelve months from the date of this filing causing us to have substantial doubt of our ability to continue as a going concern.”View the 10-Q filed Aug 17, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Sep 1, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Sep 1, 2026.
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FEED
this stock
ENvue Medical, Inc.
|
$3.98M | — | +33.1% | — | 3.1% |
|
ABT
Abbott Laboratories
|
$192.64B | -11.8% | +5.7% | 31.0 | 1.2% |
|
SYK
Stryker Corp
|
$121.41B | -11.2% | +11.2% | 32.8 | 1.8% |
|
MDT
Medtronic plc
|
$117.82B | -4.0% | +8.4% | 24.7 | 1.1% |
|
BSX
Boston Scientific Corp
|
$70.10B | -49.3% | +12.5% | 19.6 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Sep 1, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FEED | — | — | — | — | — |
| SPY | -0.1% | -0.6% | +14.9% | -0.3% | +12.2% |
| vs SPY | — | — | — | — | — |